Jason Lettman has joined Morgenthaler Ventures as a vice president, focused on medical device investments. He will be based in the firm’s Menlo Park office, and previously was a vice president with Split Rock Partners.
Morgenthaler Ventures (www.morgenthaler.com), a leading venture capital firm, announced today that Jason Lettmann has joined its Life Science Team as vice president. Lettmann joined Morgenthaler’s Menlo Park, CA, office in June of this year and will focus primarily on medical device investments.
Prior to Morgenthaler, Lettmann was vice president at Split Rock Partners where he focused on venture investments in the medical device sector. Lettmann was a co-founder and is currently a member of the Board of Directors of Yeti Medical. During his tenure at Split Rock, Lettmann was active in the incubation and continued progress of Ardian, The Foundry, ForSight Labs, Cabochon Aesthetics and Miramar Labs – all of which are also Morgenthaler portfolio companies.
“Having worked with Jason for several years on our portfolio companies, we know firsthand the domain expertise and dedication he brings to the Morgenthaler team. We are pleased to welcome Jason aboard at a time when we are very excited about the investment opportunities in life sciences,” said Hank Plain, partner at Morgenthaler.
Prior to Split Rock, Lettmann was a consultant with Accenture’s Health and Life Science practice, where he advised clients across the medical device, pharmaceutical and health payer sectors. His previous experience also includes tenure with Guidant Corporation’s Compass and West Coast business development group and as a genetic research analyst at the University of Iowa Hospitals and Clinics. He holds an MBA with distinction from the University of Michigan’s Ross School of Business and a BA with honors from the University of Iowa.
Morgenthaler is a leading, national venture capital and private equity firm with offices in Boston, MA; Boulder, CO; Cleveland, OH and Menlo Park, CA. It has funded more than 300 companies over 40 years and currently has approximately $3 billion under management. Morgenthaler has three distinct investment teams: the Life Science Team, the Information Technology Team and the Private Equity Team. Morgenthaler closed MVP IX, a $400-million venture capital fund, in November of 2008.
The Life Science Team focuses on venture capital investments in biotechnology and medical devices. Recent investments include: Ardian, Avidia, Cabochon, CardioMind, Catalyst Biosciences, ForSight, IPC The Hospitalist Company, Morphotek, Moximed, OncoMed Pharmaceuticals, Optiscan, Orexigen, Promedior, Relievant, Transcend Medical, Satiety and Vertiflex.